ClinicalTrials.gg
CompletedNCT05471817Updated Nov 22, 2022

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

A Phase 1 interventional study of Elinzanetant (BAY3427080) and Dabigatran etexilate in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes and Healthy Volunteers, sponsored by Bayer. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-22.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
10th of 13
20 · median 64
Started
2022
with 4 others
Phase 1
7 of 13
none open now
Registered
10th of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 10th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 1, and was the 10th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.

The study drug, elinzanetant, is under development to treat symptoms caused by hormonal changes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.

Participants of this study will be healthy and will have no benefit from administration of elinzanetant. This study, however, will provide information on how to use elinzanetant in people with vasomotor symptoms.

The main purpose of this study is to learn whether the study drug elinzanetant (BAY3427080) affects the way the substrate drug dabigatran moves into, through and out of the body.

One way of removing substances such as drugs from the body are proteins which act as transporters. One such transporter is called P-gp. As a so-called substrate of P-gp, dabigatran is typically removed from the body by P-gp transporters.

The activity of transporters can be increased by substances called inducers and decreased by substances called inhibitors. It has been found in laboratory experiments that the study drug elinzanetant is a weak inhibitor of the P-gp transporter. Inhibition of this transporter can lead to an increase in the amount of drugs such as dabigatran in the blood.

This study is therefore needed to make recommendations on how elinzanetant can be used safely together with other drugs that are removed from the body by the P-gp transporter.

To answer this, the researchers will compare

  • the average highest level of dabigatran in the blood (also referred to as Cmax)
  • the average total level of dabigatran in the blood (also referred to as AUC) when dabigatran is given alone and is given together with elinzanetant. All participants will take one dose of dabigatran by mouth in the first period of the study. And after 4 days, the participants will take one dose of elinzanetant by mouth and at 30 minutes later, one dose of dabigatran by mouth during the second period of the study. The total duration of individual study participation will be about 4.5 weeks including the screening period. Each participant will stay in the center for 9 days with 8 overnight stays.

During the study, the study team will:

  • take blood and urine samples
  • do physical examinations
  • check the participants' overall health
  • examine heart health using ECG
  • check vital signs
  • ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

03

Conditions studied

  • Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
  • Hot Flashes
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 65 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, blood pressure (BP), pulse rate, 12-lead (ECG), and laboratory tests.
  • Body weight of at least 50 kg and (BMI) above or equal 18.0 and below or equal 30.0 kg/m² at screening.
  • Male or female
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Known to any study intervention (active substances or of the preparations) to be used in the study.
  • Thyroid-stimulating hormone (TSH) outside normal range at screening.
  • Any lesion or condition considered a significant risk factor for major bleeding.
  • Known or suspected coagulopathies.
  • Estimated (eGFR according to Chronic Kidney Disease Epidemiology Collaboration; CKD-EPI) below 90 mL/min/1.73 m2 at screening.
  • Any use of systemic or topically active medication or herbal remedies, prescription or non-prescription, within 2 weeks or 5 half-lives (whichever longer) prior to the first study intervention administration.
  • Suspicion of drug or alcohol abuse.
  • Smoker (current, or within 6 months before screening).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    EZN - DBG

    Participants will receive a single oral dose of dabigatran (DBG) etexilate in fasted state in Period 1; followed by a single oral dose of elinzanetant (EZN) and DBG etexilate (30 min after EZN) in fasted state in Period 2.

    Drug: Elinzanetant (BAY3427080) · Drug: Dabigatran etexilate

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of unconjugated and total dabigatran when given without or together with a single oral dose of elinzanetant

    Cmax: maximum observed drug concentration in plasma after single dose

    Time frame: Pre-dose and up until 72 hours post-dose of DBG etexilate

  2. AUC of unconjugated and total dabigatran when given without or together with a single oral dose of elinzanetant

    AUC(0-tlast) will be the primary endpoint if AUC cannot be determined in all participants. AUC: area under the concentration vs. time curve from zero to infinity after single dose; AUC(0-tlast): area under the concentration vs. time curve from zero to last quantifiable concentration after single dose

    Time frame: Pre-dose and up until 72 hours post-dose of DBG etexilate

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: After first study intervention in Period 1 and up to 72.5 hours post-dose of elinzanetant in Period 2 (around 8 days)

  2. Number of participants with treatment-emergent adverse events (TEAEs) categorized by severity

    Time frame: After first study intervention in Period 1 and up to 72.5 hours post-dose of elinzanetant in Period 2 (around 8 days)

07

Study locations

1 site
  • CRS Clinical Research Services Wuppertal GmbH
    Wuppertal, Nordrhein-Westfalen 42113, Germany
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Sep 2022, 1 month.

Of 10 phase 1 interventional studies under Hot Flashes, half reached primary completion within 3 months of starting (the median); a quarter within 1 and three quarters within 9. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2022
First posted
Jul 25, 2022
StartActual
Aug 5, 2022
Primary completionActual
Sep 20, 2022
CompletionActual
Nov 14, 2022
Last update
Nov 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05471817
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 25, 2022
Start date
Aug 5, 2022
Primary completion
Sep 20, 2022
Completion
Nov 14, 2022
Last update
Nov 22, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elinzanetant · Dabigatran

Start the discussion